



Professor Kenneth Chien Scientific Advisor to Bactiguard

Professor Kenneth Chien becomes Scientific Advisor to Bactiguard and will also lead the company's Scientific Board. Professor Chien is an internationally recognized leader and pioneer in cardiovascular science. In 2013, he was recruited to Karolinska Institutet from Harvard University, USA.

"Hospital Acquired infections are an increasing problem worldwide. Bacteria resistant to several types of antibiotics are increasing and healthcare costs are soaring. Bactiguard's technology holds great promise for the millions of cardiovascular patients who are receiving catheterization and implantation of devices every day. Diabetes is a major risk factor for hospital acquired infections and the major driver of heart disease worldwide.

The coating developed by Bactiguard could play a major role in reducing the incidence of hospital acquired infections in patients, in both developing and developed nations in the near term. The cost effectiveness of the technology is also appealing and the fact that it would largely escape the problem of creating new antibiotic resistant infective agents," says Professor Kenneth Chien.

You will find an interview with Professor Chien, among others, via this link:

https://www.youtube.com/watch?v=YxMBxC5J_Sw

"We are honoured and proud that Professor Chien has accepted to become a strategic Scientific Advisor to Bactiguard. Kenneth Chien is an internationally recognized leader in regenerative medicine and cardiovascular science.

The partnership with Professor Chien is a major recognition of Bactiguard and our technology to prevent hospital acquired infections, one of the greatest challenges of our time. At the same time, it opens up exciting possibilities to develop new applications and explore new therapeutic areas, where Bactiguard's technology can be applicable. Professor Chien's contribution to the strategic discussions of the Bactiguard Board will be invaluable," says Christian Kinch, Chairman of the Board.

Professor Kenneth R Chien MD, PhD

Professor Kenneth Chien received a Presidential appointment as a Professor to Karolinska Institutet, in 2013. He is an internationally recognized leader in cardiovascular science, as well as a pioneer in developing new therapeutic strategies to prevent the onset and progression of heart failure. At Karolinska Institutet, Professor Chien leads a team of physicians and scientist on the pathways for human cardiogenesis, with a goal of finding new insights into congenital heart disease in children, as well as novel pathways and principles for regenerative medicine and the repair of damaged cardiac muscle cells.

Professor Kenneth Chien was previously the Charles and Elizabeth Ann Sanders Professor in the Department of Stem Cell and Regenerative Biology at Harvard University in Cambridge, USA. In July 2005, he was appointed as Scientific Director of the Cardiovascular Research Center at Massachusetts General Hospital in Boston. He is a recipient of the Pasarow Foundation Award and a member of the Norwegian Academy of Sciences, the Austrian Academy of Sciences, and honorary doctorate of the University of Edinburgh for his work. Recently he was appointed as a Distinguished Professorship of the Swedish Research Council, and Director of the Karolinska-Wallenberg Cardiovascular Initiative.

For further information, please contact:

Cecilia Edström - Director of Communications

cecilia.edstrom@bactiguard.se

+46 72 226 23 28

Bactiguard

Bactiguard is a Swedish medtech company with a business concept of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company's patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported sales of approximately SEK 130 million in 2013, has 60 employees, headquarters in Stockholm and production facilities in Markaryd and Malaysia.